Nanjing Transthera Biosciences Co. Ltd.

Ford Global Technolgoies, LLC

Transthera Sciences (Nanjing), Inc.

Transthera Sciences, Inc.

Frank Wu

Lin Li

Xiaoju Yang

Tom Xu

Peter Zhang

Bo Chen

Tony Wang

Luther Wang

Zhonghui Wan

Rose Tong

James Eum

Charlene Chen

Zejuan Sheng

Peng Peng

Xiaoyan Qiang

Disclosed are uses of a compound represented by general formula (I) and pharmaceutically acceptable salts, isomers and deuterated compounds thereof in the preparation of a medicine for treating heart failure diseases. Experiments prove that the compound can improve the heart function of rats with heart failure, reverse myocardial remodeling caused by heart failure, and reduce fibrosis in the marginal zone of infarction.

Uses of phosphodiesterase inhibitors

The present invention relates to the technical field of pharmaceuticals. Specifically, the present invention relates to a halo-allylamine compound, or a pharmaceutically acceptable salt, an ester, a stereoisomer or a tautomer thereof, and a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, and use in preventing and/or treating a disease related to or mediated by the SSAO/VAP-1 protein, wherein R, R, R, R, R, R, Land Cyare defined in the specification.

Haloallylamine compounds and application thereof

The present invention relates to a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R, R, X, Y, P, W, and Ar are as defined in the description. Also provided is a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-]pyrido[4,3-][1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4&#xb1;0.2&#xb0;, 17.9&#xb1;0.2&#xb0;, 18.9&#xb1;0.2&#xb0;, 19.4&#xb1;0.2&#xb0;, 21.5&#xb1;0.2&#xb0;, and 23.7&#xb1;0.2&#xb0;.

Method for treating a cancer mediated by abnormality of multi-kinases

The present invention belongs to the pharmaceutical technical field, and specifically relates to a haloallylamine compound represented by formula I, a pharmaceutically acceptable salt, an ester or a stereoisomer thereof, R, R, R, R, R, R, L, C, Rare defined as in the specification; the present invention also relates to pharmaceutical preparations and pharmaceutical compositions containing these compounds, and their use in preventing and/or treating the SSAO/VAP-1 protein-related or SSAO/VAP-1 protein-mediated disease. 

Halo-allylamine SSAO/VAP-1 inhibitor and use thereof

The present invention falls within the technical field of medicine, and in particular relates to PDE9 inhibitor compounds as shown in formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, and also relates to pharmaceutical preparations and pharmaceutical compositions of the compounds and the uses thereof. X, X, X, X, R, R, ring A, L and m are as defined in the description. The compounds can be used to prepare drugs for treating or preventing related diseases mediated by PDE9. 

PDE9 inhibitor and use thereof

The present invention belongs to the field of medical technology. Particularly, the present invention relates to a compound shown in formula (I), a pharmaceutically acceptable salt thereof, and a stereoisomer of the same. X, Y, Z, R, R, R, R, R, m, and n are as defined in the specification. The present invention also relates to pharmaceutical preparations and pharmaceutical compositions of these compounds and a use thereof in preparing a drug for treating a related disease mediated by abnormal indoleamine 2,3-dioxygenase (IDO). 

Indoleamine 2,3-dioxygenase inhibitor and application

The present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R, R, X, Y, P, W, and Ar are as defined in the description. The compound of formula (I) of the present invention can be used in the preparation of a drug for treating cancers mediated by abnormality of multi-kinases. Also provided is a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4&#xb1;0.2&#xb0;, 17.9&#xb1;0.2&#xb0;, 18.9&#xb1;0.2&#xb0;, 19.4&#xb1;0.2&#xb0;, 21.5&#xb1;0.2&#xb0;, and 23.7&#xb1;0.2&#xb0;. 

Multi-kinase inhibitor compound, and crystal form and use thereof

Provided are an irreversible inhibitor of a fibroblast growth factor receptor (FGFR) as indicated by formula I, a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical preparation, a pharmaceutical composition and an application thereof. R, R, R, R, ring A, Ar, ring B and warhead are as defined in the specification. The compound has high-efficiency and high-selectivity inhibition of a fibroblast growth factor receptor and can be applied to treatment of abnormal FGF/FGFR-mediated diseases, in particular the treatment of cancers. 

Inhibitors of fibroblast growth factor receptor and use thereof

The present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. The compound of formula (I) of the present invention can be used in the preparation of a drug for treating cancers mediated by abnormality of multi-kinases. Also provided is a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e] [1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4&#xb1;0.2&#xb0;, 17.9&#xb1;0.2&#xb0;, 18.9&#xb1;0.2&#xb0;, 19.4&#xb1;0.2&#xb0;, 21.5&#xb1;0.2&#xb0;, and 23.7&#xb1;0.2&#xb0;. 

A control system for a vehicle having a seat with a first moveable portion and an adjustment actuator coupled with the first moveable seat portion includes a voice input device, a touchscreen input device, and a controller in communication with the adjustment actuator, the voice input device, and the touchscreen input device. The controller has a processor programmed to interpret a first adjustment command from one of a voice command received from the voice input device and a manual command received from the touchscreen input device, carry out a first seat adjustment by causing the adjustment actuator to move the first moveable seat portion according to the first adjustment command, and to present information related to the first adjustment command on the touchscreen.

System and methods for voice-controlled seat adjustment

According to one or more embodiments, a seat climate control assembly for a seat includes a seatback and a headrest, the seat climate control assembly includes an air intake port positioned on a top portion of the seatback and in fluid communication with the headrest, and an air controller in fluid communication with the air intake port.

Seat climate control assembly and seat employing the same

The present invention in one or more embodiments provides a compartment panel assembly to be positioned between one or more seats and a trunk storage of a vehicle. The compartment panel includes a panel portion, a protruding portion extending from the panel portion and including a first wall which defines thereupon a first aperture, and a first storage container to be at least partially received through the first aperture. The present invention in one or more embodiments is advantageous positioned in providing effective storage within the vehicle interior, and in particular providing storage spaces that are lockable and/or not directly visible for enhanced storage security.

Growing community of inventors

Nanjing, China

Frank Wu